SUPPORTING INFECTIOUS DISEASE RESEARCH

# Monoclonal Anti-Influenza A Virus H3 Hemagglutinin (HA), A/Hong Kong/2286/2017 (H3N2), Clone HK17-4 (ascites, Mouse)

### Catalog No. NR-52364

This reagent is the tangible property of the U.S. Government.

#### **Product Description:**

Mouse monoclonal antibody (clone HK17-4) reactive with the H3 hemagglutinin (HA) of the A/Hong Kong/2286/2017 strain of influenza virus was produced in mouse ascites.

#### Lot: 70037381

# Manufacturing Date: FEB2020

TEST	SPECIFICATIONS	RESULTS
Functional Activity <sup>1,2</sup>		
Hemagglutinin inhibition (HI) titer with homologous virus		
A/Hong Kong/2286/2017 (H3N2)	Report results	1:800
HI assay with antigens representing 16 HA subtypes	Specific to H3 HA subtype	Specific to H3 HA subtype
HI titers with H3 influenza virus		
Human types:		
A/Victoria/361/2011 (H3N2)	Report results	1:400
A/Texas/50/2012 (H3N2)	Report results	1:400
A/Hong Kong/4801/2014 (H3N2)	Report results	1:200
A/Singapore/INFIMH-16-0019/2016 (H3N2)	Report results	1:100
A/Switzerland/8060/2017 (H3N2)	Report results	1:400
Avian (swine) types:		
A/swine/Ohio/16TOSU4783/2016 (H3N2)	Report results	1:400
A/swine/Illinois/TM1707DTW18/2017 (H3N2)	Report results	1:400
Sterility	Report results	Low bioburden

<sup>1</sup>Tests performed at St. Jude Children's Research Hospital

<sup>2</sup>HI assays were performed with 0.5% turkey red blood cells (TRBCs).

# /Heather Couch/ Heather Couch

Program Manager or designee, ATCC Federal Solutions

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the contractor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

Support Provided by NIAID

24 FEB 2021